Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer.
CTCs
aggressive variant prostate cancer
large extracellular vesicles
liquid biopsy
metastatic castrate-resistant prostate cancer
oncosomes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
20
01
2021
revised:
16
02
2021
accepted:
24
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Liquid biopsies hold potential as minimally invasive sources of tumor biomarkers for diagnosis, prognosis, therapy prediction or disease monitoring. We present an approach for parallel single-object identification of circulating tumor cells (CTCs) and tumor-derived large extracellular vesicles (LEVs) based on automated high-resolution immunofluorescence followed by downstream multiplexed protein profiling. Identification of LEVs >6 µm in size and CTC enumeration was highly correlated, with LEVs being 1.9 times as frequent as CTCs, and additional LEVs were identified in 73% of CTC-negative liquid biopsy samples from metastatic castrate resistant prostate cancer. Imaging mass cytometry (IMC) revealed that 49% of cytokeratin (CK)-positive LEVs and CTCs were EpCAM-negative, while frequently carrying prostate cancer tumor markers including AR, PSA, and PSMA. HSPD1 was shown to be a specific biomarker for tumor derived circulating cells and LEVs. CTCs and LEVs could be discriminated based on size, morphology, DNA load and protein score but not by protein signatures. Protein profiles were overall heterogeneous, and clusters could be identified across object classes. Parallel analysis of CTCs and LEVs confers increased sensitivity for liquid biopsies and expanded specificity with downstream characterization. Combined, it raises the possibility of a more comprehensive assessment of the disease state for precise diagnosis and monitoring.
Identifiants
pubmed: 33801459
pii: cancers13051056
doi: 10.3390/cancers13051056
pmc: PMC7958848
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Prostate Cancer Foundation
ID : 17CHAL01
Organisme : USC Norris Comprehensive Cancer Center (CORE)
ID : 5P30CA014089-40
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : Breast Cancer Research Foundation
ID : 20-089
Organisme : Swedish Research Council
ID : 2015-06510
Références
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Proteomics. 2019 Jan;19(1-2):e1800169
pubmed: 30561828
Lancet Oncol. 2019 Oct;20(10):1432-1443
pubmed: 31515154
Nat Med. 2012 Dec;18(12):1835-40
pubmed: 23142818
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Phys Biol. 2015 Jan 09;12(1):016008
pubmed: 25574741
Cell Stress Chaperones. 2011 May;16(3):235-49
pubmed: 20963644
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 32670616
J Transl Med. 2019 Aug 28;17(1):294
pubmed: 31462312
Cancer Res. 2009 Jul 1;69(13):5601-9
pubmed: 19549916
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
ACS Nano. 2018 Jan 23;12(1):494-503
pubmed: 29286635
PLoS One. 2014 Oct 17;9(10):e110443
pubmed: 25329303
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
Eur Urol. 2020 Feb;77(2):170-177
pubmed: 31648903
Acta Biomater. 2021 Apr 1;124:88-107
pubmed: 33454381
J Extracell Vesicles. 2016 Sep 27;5:33109
pubmed: 27680302
Cells. 2020 Dec 08;9(12):
pubmed: 33302515
Int J Mol Sci. 2019 Sep 17;20(18):
pubmed: 31533245
Arch Pathol Lab Med. 2018 Feb;142(2):198-207
pubmed: 29144792
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 30906572
PLoS One. 2014 Aug 01;9(8):e101777
pubmed: 25084170
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
Cells. 2019 Aug 20;8(8):
pubmed: 31434250
Clin Cancer Res. 2020 Aug 1;26(15):4143-4153
pubmed: 32341031
Cells. 2020 Feb 02;9(2):
pubmed: 32024251
Oncotarget. 2015 May 10;6(13):11327-41
pubmed: 25857301
Nat Commun. 2018 Jan 12;9(1):175
pubmed: 29330365
Cell Prolif. 2019 Nov;52(6):e12659
pubmed: 31469460
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
Ann Oncol. 2010 Sep;21(9):1851-1857
pubmed: 20147742
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):251-258
pubmed: 28374743
Oncotarget. 2019 Dec 17;10(66):7016-7030
pubmed: 31903162
Cytometry A. 2004 Nov;62(1):46-53
pubmed: 15472900
Am J Pathol. 2012 Nov;181(5):1573-84
pubmed: 23022210
Semin Cell Dev Biol. 2017 Jul;67:11-22
pubmed: 28077296
Clin Cancer Res. 2017 Apr 1;23(7):1722-1732
pubmed: 27702818
Lab Chip. 2019 Jul 23;19(15):2526-2536
pubmed: 31292600
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394
Eur Urol. 2017 Jun;71(6):874-882
pubmed: 27979426
Semin Cancer Biol. 2015 Dec;35:191-9
pubmed: 26241348
Clin Cancer Res. 2016 Mar 15;22(6):1520-30
pubmed: 26546618